0 Replies
... By knock down of target receptor by rnai technology contact requests for information and applications directly to: ms.H.S. Narayanan, chief administration, icgeb New delhi component aruna asaf ali ... Contine Reading & Discuss→
0 Replies
An original paper entitled 'microRNAs in CNS disorders by Jannet Kocerha and Claes Wahlestedt (Scripps Research Institute, Florida) and Sakari Kauppinen, Santaris Pharma has been published in Neuromol Med.
Abstract
read more Contine Reading & Discuss→
0 Replies
BOULDER, Colo. & CAMBRIDGE, Mass., July 23, 2009 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, and Archemix Corp., a biotechnology company focused on developing aptamer therapeutics, announced today that the two companies will collaborate on conjugated aptamer-microRNA therapies capable... Contine Reading & Discuss→
0 Replies
Santaris Pharma A/S chairs the session 'RNAi, microRNA and Antisense as antivirals' at the World Summit of Antivirals in Beijing, China on July 20, 2009 and gives a presentation Contine Reading & Discuss→
0 Replies
Santaris Pharma A/S today announced that Nucleic Acid Research Advance Access on July 13 published a paper on silencing microRNA-155 in mice.
The paper is entitled "Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF."
Authors: Jesper Worm, Jan Stenvang,... Contine Reading & Discuss→
